A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies.

Lachowiez CA., Borthakur G., Loghavi S., Zeng Z., Kadia TM., Masarova L., Takahashi K., Tippett GD., Smith S., Garcia JS., Bose P., Jabbour E., Ravandi F., Daver NG., Garcia-Manero G., Stoilova B., Vyas P., Kantarjian HM., Konopleva M., Dinardo CD.

DOI

10.1200/JCO.2021.39.15_suppl.7012

Type

Conference paper

Publication Date

20/05/2021

Volume

39

Permalink Original publication